LTR Pharma (ASX:LTP) has joined forces with Strategic Drug Solutions to developed a nasal spray to treat oesophageal motility ...

Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows.

Neffy ® (epinephrine nasal spray) 1 mg is now available for the emergency treatment of type 1 allergic reactions, including anaphylaxis, in pediatric patients aged 4 years and older weighing 15 to ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the US, providing a new option ...

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first needle-free alternative to EpiPen-style autoinjectors for serious allergic reactions. The green light ...

Courtesy Lowenthal For decades, people suffering life-threatening allergic reactions had to quickly and correctly give ...

Topical deep delivery of corticosteroids into the sinonasal cavity improves symptoms and sleep in patients with chronic rhinosinusitis.

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...